NCT02227940 - Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2015

Primary Completion Date

December 27, 2018

Study Completion Date

February 12, 2019

Conditions

Advanced Malignant Solid NeoplasmALK PositiveMetastatic Pancreatic AdenocarcinomaStage III Pancreatic CancerStage IV Pancreatic Cancer

Interventions

DRUG

Ceritinib

Given PO

DRUG

Cisplatin

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

Roswell Park Cancer Institute, Buffalo